TY - JOUR
T1 - Severe acute interstitial pneumonia and gefitinib
AU - Inoue, Akira
AU - Saijo, Yasuo
AU - Maemondo, Makoto
AU - Gomi, Kazunori
AU - Tokue, Yutaka
AU - Kimura, Yuichiro
AU - Ebina, Masahito
AU - Kikuchi, Toshiaki
AU - Moriya, Takuya
AU - Nukiwa, Toshihiro
N1 - Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2003/1/11
Y1 - 2003/1/11
N2 - Gefitinib is an oral selective inhibitor of the epidermal growth factor receptor tyrosine kinase that is an effective treatment for patients with advanced non-small cell lung cancer who do not respond to platinum-based chemotherapy. We assessed four patients who had non-small cell lung cancer causing severe acute interstitial pneumonia in association with gefitinib. Although two patients recovered after treatment with steroids, the other two died from progressive respiratory dysfunction. On the basis of autopsies and bilateral distribution of diffuse ground-glass opacities in chest CTs, we diagnosed diffuse alveolar damage, which was consistent with acute interstitial pneumonia. Patients with interstitial pneumonia also had other pulmonary disorders such as previous thoracic irradiation and poor performance status. Physicians should be aware of the alveolar damage induced by gefitinib, especially for patients with these characteristic features.
AB - Gefitinib is an oral selective inhibitor of the epidermal growth factor receptor tyrosine kinase that is an effective treatment for patients with advanced non-small cell lung cancer who do not respond to platinum-based chemotherapy. We assessed four patients who had non-small cell lung cancer causing severe acute interstitial pneumonia in association with gefitinib. Although two patients recovered after treatment with steroids, the other two died from progressive respiratory dysfunction. On the basis of autopsies and bilateral distribution of diffuse ground-glass opacities in chest CTs, we diagnosed diffuse alveolar damage, which was consistent with acute interstitial pneumonia. Patients with interstitial pneumonia also had other pulmonary disorders such as previous thoracic irradiation and poor performance status. Physicians should be aware of the alveolar damage induced by gefitinib, especially for patients with these characteristic features.
UR - http://www.scopus.com/inward/record.url?scp=0037431759&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037431759&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(03)12190-3
DO - 10.1016/S0140-6736(03)12190-3
M3 - Article
C2 - 12531582
AN - SCOPUS:0037431759
VL - 361
SP - 137
EP - 139
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 9352
ER -